Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
BeiGene, Ltd. (ONC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/18/2025: ONC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
24 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $401.52
1 Year Target Price $401.52
| 15 | Strong Buy |
| 8 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -34.4% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/18/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 33.97B USD | Price to earnings Ratio 590.42 | 1Y Target Price 401.52 |
Price to earnings Ratio 590.42 | 1Y Target Price 401.52 | ||
Volume (30-day avg) 24 | Beta 0.46 | 52 Weeks Range 172.67 - 385.22 | Updated Date 12/19/2025 |
52 Weeks Range 172.67 - 385.22 | Updated Date 12/19/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.52 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 1.38% | Operating Margin (TTM) 11.55% |
Management Effectiveness
Return on Assets (TTM) 1.69% | Return on Equity (TTM) 1.81% |
Valuation
Trailing PE 590.42 | Forward PE 37.59 | Enterprise Value 32773750783 | Price to Sales(TTM) 6.83 |
Enterprise Value 32773750783 | Price to Sales(TTM) 6.83 | ||
Enterprise Value to Revenue 6.59 | Enterprise Value to EBITDA 96.79 | Shares Outstanding 101807539 | Shares Floating 882969613 |
Shares Outstanding 101807539 | Shares Floating 882969613 | ||
Percent Insiders 17.3 | Percent Institutions 31.06 |
Upturn AI SWOT
BeiGene, Ltd.
Company Overview
History and Background
BeiGene, Ltd. was founded in 2010 by Xiaodong Wang, M.D., Ph.D., and John Oyler. It is a global biotechnology company focused on the discovery, development, and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. Significant milestones include the development and commercialization of several key oncology drugs, strategic partnerships with global pharmaceutical companies, and expansion into major markets worldwide. The company has evolved from a discovery-stage entity to a fully integrated biopharmaceutical company with a growing commercial presence.
Core Business Areas
- Oncology Drug Development: BeiGene's core business revolves around the discovery and development of novel therapies for cancer. This includes a broad pipeline of small molecule drugs and biologics targeting various cancer pathways, including Bruton's tyrosine kinase (BTK), epidermal growth factor receptor (EGFR), and PD-1/PD-L1 interactions.
- Commercialization and Sales: The company is increasingly focused on the commercialization of its approved products in key global markets, including China, the United States, Europe, and Japan. This involves building and expanding its sales and marketing infrastructure.
- Research and Development: BeiGene invests heavily in R&D to fuel its pipeline. This includes in-house discovery capabilities and collaborations with academic institutions and other biotech companies.
Leadership and Structure
BeiGene is led by a management team with extensive experience in the biopharmaceutical industry. Key leaders include John Oyler (Co-Founder, Chairman, and CEO) and Amy Peterson, M.D. (Chief Medical Officer). The company operates with a global structure, with R&D centers and commercial operations across multiple continents.
Top Products and Market Share
Key Offerings
- Brukinsa (zanubrutinib): A potent and selective Bruton's tyrosine kinase (BTK) inhibitor for the treatment of various B-cell malignancies, including mantle cell lymphoma (MCL), Waldenstru00f6m's macroglobulinemia (WM), and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Competitors include AbbVie's Imbruvica (ibrutinib) and AstraZeneca's Calquence (acalabrutinib). Brukinsa has shown strong growth and has gained significant market share in its approved indications.
- Tislelizumab (Tevimbra): A humanized IgG4 anti-PD-1 antibody designed to selectively bind to PD-1 and block its interaction with PD-L1 and PD-P1. It is approved for several indications in China, including esophageal squamous cell carcinoma, nasopharyngeal carcinoma, and urothelial carcinoma, and has ongoing development in global markets. Competitors include Merck's Keytruda (pembrolizumab), Bristol Myers Squibb's Opdivo (nivolumab), and AstraZeneca's Imfinzi (durvalumab).
- Pamiparib: A potential best-in-class PARP inhibitor for the treatment of various cancers, including ovarian cancer and gastric cancer. It is in late-stage clinical development.
Market Dynamics
Industry Overview
The global oncology market is characterized by rapid innovation, significant unmet medical needs, and increasing patient access to advanced therapies. Targeted therapies and immunotherapies are driving significant growth, with a strong emphasis on personalized medicine and combination treatments. The biopharmaceutical industry is highly competitive and heavily regulated, with substantial R&D investment required.
Positioning
BeiGene is positioned as a leading global oncology company with a strong pipeline of innovative therapies. Its key competitive advantages include its robust R&D capabilities, a diversified product portfolio covering multiple cancer types, and a strategic focus on both emerging and developed markets. The company's ability to develop drugs for both global and China-specific needs is a unique strength.
Total Addressable Market (TAM)
The total addressable market for oncology drugs is vast and continues to grow, estimated to be in the hundreds of billions of US dollars annually. BeiGene is positioned to capture a significant portion of this TAM by developing and commercializing innovative treatments for various cancers. Its current and pipeline products address major cancer indications with substantial patient populations.
Upturn SWOT Analysis
Strengths
- Strong R&D pipeline with multiple promising drug candidates.
- Successful development and commercialization of key oncology drugs (Brukinsa, Tislelizumab).
- Global operational presence and market access, particularly in China and the US.
- Experienced leadership team with a proven track record in drug development and commercialization.
- Strategic partnerships with leading pharmaceutical companies.
Weaknesses
- Reliance on a few key products for revenue generation.
- High R&D expenditure, leading to significant cash burn.
- Competition from established pharmaceutical giants with larger market share and resources.
- Potential for pricing pressures and regulatory hurdles in different markets.
Opportunities
- Expansion of existing drug indications and development of new ones.
- Further penetration into global markets, including Europe and Japan.
- Development of novel combination therapies.
- Leveraging AI and big data for drug discovery and development.
- Strategic acquisitions to bolster pipeline or expand market reach.
Threats
- Clinical trial failures or delays.
- Intensifying competition from both established and emerging biotech companies.
- Changes in regulatory policies and reimbursement landscapes.
- Patent expirations and generic competition for future products.
- Global economic downturn impacting healthcare spending.
Competitors and Market Share
Key Competitors
- AbbVie Inc. (ABBV)
- AstraZeneca PLC (AZN)
- Bristol Myers Squibb Company (BMY)
- Merck & Co., Inc. (MRK)
- Pfizer Inc. (PFE)
Competitive Landscape
BeiGene faces intense competition from large pharmaceutical companies with established oncology portfolios and significant market penetration. However, BeiGene's competitive advantages lie in its focused approach to oncology, its innovative pipeline, and its strong presence in the Chinese market, which is a significant and growing contributor to the global oncology landscape.
Growth Trajectory and Initiatives
Historical Growth: BeiGene has experienced rapid historical growth in terms of revenue and pipeline advancement. The successful clinical development and commercial launch of Brukinsa has been a key driver of this growth. The company has consistently expanded its R&D capabilities and global footprint.
Future Projections: Analysts project continued strong revenue growth for BeiGene in the coming years, driven by the expanding use of Brukinsa and the anticipated approvals and launches of other pipeline assets, such as Tislelizumab in new markets. Profitability is expected to improve as revenue scales and R&D efficiency increases, though significant investments will likely continue.
Recent Initiatives: Recent initiatives include the expansion of Brukinsa's label to new indications, ongoing global clinical trials for Tislelizumab, and strategic collaborations to advance its pipeline. The company has also focused on strengthening its commercial infrastructure in key markets.
Summary
BeiGene, Ltd. is a rapidly growing global biotechnology company with a strong focus on oncology. Its flagship product, Brukinsa, has demonstrated significant success, driving substantial revenue growth. While the company faces intense competition and continued R&D investment demands, its robust pipeline and expanding global presence position it for future success. Key areas to monitor include clinical trial outcomes, regulatory approvals in new markets, and the company's ability to manage its cash burn effectively.
Similar Stocks
Sources and Disclaimers
Data Sources:
- BeiGene, Ltd. Investor Relations Filings (SEC)
- Industry Analyst Reports
- Biotechnology Industry Databases
- Financial News Outlets
Disclaimers:
This JSON output is for informational purposes only and does not constitute financial advice. Data accuracy is based on publicly available information and may be subject to change. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BeiGene, Ltd.
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2016-02-03 | Co-Founder, Executive Chairman & CEO Mr. John V. Oyler | ||
Sector Healthcare | Industry Biotechnology | Full time employees 11000 | Website https://beonemedicines.com |
Full time employees 11000 | Website https://beonemedicines.com | ||
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; Ociperlimab (BGB-A1217), a TIGIT inhibitor; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.